Annagrazia Pireddu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Annagrazia Pireddu has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Pretta
Medical Oncology Unit, University Hospital and University of Cagliari, Italy
3 shared publications - Clelia Donisi
Medical Oncology Unit, University Hospital and University of Cagliari, 09042 Cagliari, Italy
3 shared publications - Eleonora Lai
Medical Oncology Unit, University Hospital and University of Cagliari, 09042 Cagliari, Italy
3 shared publications - Francesca Balconi
Medical Oncology Unit, University Hospital and University of Cagliari, 09042 Cagliari, Italy
3 shared publications - Francesca Musio
Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy. Oncologia Medica, Azienda Ospedaliera Universitaria di Cagliari, Presidio Policlinico Universitario "Duilio Casula" S.S. 554, Km 4,500 Bivio per Sestu, 09042 Monserrato, Cagliari, Italy
3 shared publications - Mara Persano
Department of Oncology Vita‐Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital Milan Italy
3 shared publications
Latest Publications
- 1 January 2021
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 157, 103167
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
- 1 January 2021
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 157, 103167
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
- Open Access
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer
Background: Metastatic CRC (mCRC) is a molecular heterogeneous disease. The aim of this review is to give an overview of molecular-driven treatment of mCRC patients. Methods: A review of clinical trials, retrospective studies and case reports was performed regarding molecular biomarkers with therapeutic implications. Results: RAS wild-type status was confirmed as being crucial for anti-epidermal growth factor receptor (EGFR) monoclonal antibodies and for rechallenge strategy. Antiangiogenic therapies improve survival in first- and second-line settings, irrespective of RAS status, while tyrosine kinase inhibitors (TKIs) remain promising in refractory mCRC. Promising results emerged from anti-HER2 drugs trials in HER2-positive mCRC. Target inhibitors were successful for BRAFV600E mutant mCRC patients, while immunotherapy was successful for microsatellite instability-high/defective mismatch repair (MSI-H/dMMR) or DNA polymerase epsilon catalytic subunit (POLE-1) mutant patients. Data are still lacking on NTRK, RET, MGMT, and TGF-β, which require further research. Conclusion: Several molecular biomarkers have been identified for the tailored treatment of mCRC patients and multiple efforts are currently ongoing to increase the therapeutic options. In the era of precision medicine, molecular-biology-driven treatment is the key to impro patient selection and patient outcomes. Further research and large phase III trials are required to ameliorate the therapeutic management of these patients.
Open AccessMolecular-Biology-Driven Treatment for Metastatic Colorectal Cancer
Background: Metastatic CRC (mCRC) is a molecular heterogeneous disease. The aim of this review is to give an overview of molecular-driven treatment of mCRC patients. Methods: A review of clinical trials, retrospective studies and case reports was performed regarding molecular biomarkers with therapeutic implications. Results: RAS wild-type status was confirmed as being crucial for anti-epidermal growth factor receptor (EGFR) monoclonal antibodies and for rechallenge strategy. Antiangiogenic therapies improve survival in first- and second-line settings, irrespective of RAS status, while tyrosine kinase inhibitors (TKIs) remain promising in refractory mCRC. Promising results emerged from anti-HER2 drugs trials in HER2-positive mCRC. Target inhibitors were successful for BRAFV600E mutant mCRC patients, while immunotherapy was successful for microsatellite instability-high/defective mismatch repair (MSI-H/dMMR) or DNA polymerase epsilon catalytic subunit (POLE-1) mutant patients. Data are still lacking on NTRK, RET, MGMT, and TGF-β, which require further research. Conclusion: Several molecular biomarkers have been identified for the tailored treatment of mCRC patients and multiple efforts are currently ongoing to increase the therapeutic options. In the era of precision medicine, molecular-biology-driven treatment is the key to impro patient selection and patient outcomes. Further research and large phase III trials are required to ameliorate the therapeutic management of these patients.
- 1 December 2019
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 81, 101926
New therapeutic targets in pancreatic cancer
- 1 December 2019
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 81, 101926
New therapeutic targets in pancreatic cancer